Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

141.54 +0.08 (+0.06%)

Official Closing Price Updated: 7:00 PM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

53 54 Next >

US Stocks On Track For Nervous Start As Traders Go Fed Watching: AMD Earnings Calm Investors ↗

February 01, 2023

Futures trading point to a negative start by Wall Street stocks on Wednesday as traders exercise restraint ahead of the Fed decision due in the afternoon. Cues From Tuesday’s Trading:

Via Benzinga

Novartis Reports Mixed Bag Q4 Earnings, Forecasts Higher Sales, Profits Ahead Of Sandoz Spin-Off ↗

February 01, 2023

Via Benzinga

Envision Pharma Group Hires Leading Industry Executives Dominic Marasco and Gregory Carpenter to Lead Further Expansion of the Business and Support Growing Customer Demand

January 31, 2023

PHILADELPHIA, January 31, 2023 (Newswire.com) - Envision Pharma Group (Envision) today announced the appointment of two senior executives while further expanding its global focus on M&A,...

Via Newswire.com

7 CRISPR Stocks With the Best Long-Term Potential ↗

January 30, 2023

CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.

Via InvestorPlace

Hopeful Golden Cross Forms On Novartis's Chart ↗

December 26, 2022

Via Benzinga

5 Value Stocks In The Healthcare Sector ↗

December 26, 2022

Via Benzinga

A Bullish Sign Appears On Novartis's Chart ↗

December 23, 2022

Via Benzinga

Earnings Scheduled For February 1, 2023 ↗

February 01, 2023

Companies Reporting Before The Bell • Novo Nordisk (NYSE:NVO) is expected to report quarterly earnings at $0.85 per share on revenue of $6.84 billion.

Via Benzinga

A Preview Of Novartis's Earnings ↗

January 31, 2023

Via Benzinga

Philips Reports Q4 Earnings, To Lay Off Additional Employees This Year, Shares Jump ↗

January 30, 2023

Koninklijke Philips NV (NYSE: PHG) would reduce its workforce by an additional 6,000 roles globally by 2025, of which 3,000 will be implemented in 2023 to restore its profitability following a recall...

Via Benzinga

Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch ↗

January 29, 2023

With a full week of earnings behind us, it’s time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed.

Via Benzinga

Could This Be Novartis' Next Blockbuster Medicine? ↗

January 27, 2023

The Swiss drugmaker recently shared promising phase 3 clinical trial results for this rare-disease drug.

Via The Motley Fool

Pliant Therapeutics Gaps 34% Higher: More Upside To Come?

January 25, 2023

Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment.

Via MarketBeat

Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering ↗

January 24, 2023

Via Benzinga

3 Drug Stocks With Promising Pipelines for 2023 ↗

January 23, 2023

These 3 drug stocks with promising pipelines are in position to reward investors in 2023 due to multiple factors.

Via InvestorPlace

Clearmind Teams With Yissum, University of Jerusalem On 2 Psychedelic R&D Projects ↗

January 19, 2023

Psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) has successfully completed two drug discovery projects with leading scientists at the Hebrew University of Jerusalem.

Via Benzinga

Analyst Views Novo Nordisk's Upcoming Obesity Drug Data To Lay Grounds For Eli Lilly's Tirzepatide ↗

January 19, 2023

Cantor Fitzgerald published around 40-page deep dive ahead of Novo Nordisk A/S's (NYSE: NVO) SELECT CV outcomes study, which is guided to complete in ~mid-2023.

Via Benzinga

National Advertising Division Finds Novartis Breast Cancer Drug Claim Supported in Physician-Directed Messaging, But Not in Ads to Consumers

January 19, 2023

Via iCrowdNewswire

Drug Delivery Market – Major Technology Giants in Buzz Again : Johnson & Johnson, Sanofi, Pfizer

January 18, 2023

How to reach that market place and its associated audience with current marketing efforts? Benchmark now the competitive efforts with high growth emerging players and leaders of Drug Delivery Market.

Via SBWire

Cell and Gene Therapy Market Size, Share, Industry Analysis, Growth Estimates, Trends, Demand and Forecast 2022-2028

January 13, 2023

Global Cell and Gene Therapy Market will worth USD 21,508 million by 2028-end at a CAGR of 28.2% from 2022 to 2028 according to Intelligence Market Report

Via SBWire

Novartis CEO Refutes Recent Report Of Weighing Options For Ophthalmology, Respiratory Units ↗

January 10, 2023

Novartis AG (NYSE: NVS) said it would narrow its focus on five core therapeutic areas, including cardiovascular, immunology, neurodegenerative diseases, solid tumors, and hematology.

Via Benzinga

3 Biotech Companies to Watch in 2023 ↗

January 06, 2023

These biotech companies to watch are remarkably strong businesses that offer healthy upside potential as we head into a new year.

Via InvestorPlace

CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks ↗

January 06, 2023

Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too.

Via Investor's Business Daily

2 Top Biotech Stocks to Buy Right Now ↗

January 06, 2023

These two pharmaceutical companies pay market-beating dividends to shareholders.

Via The Motley Fool

GSK Looking For Under-Appreciated M&A Targets, Not Trying To Be Next Roche Or AstraZeneca ↗

December 30, 2022

GSK plc (NYSE: GSK) chief commercial officer Luke Miels says the company is looking at M&A targets that are under-appreciated worth $1 billion-$2.5 billion and avoid getting into a 'bidding war.'

Via Benzinga

2 Cathie Wood Stocks to Buy and Hold Through 2023 and Beyond ↗

December 29, 2022

These two biotechs are flying high right now.

Via The Motley Fool

Elon Musk Tells Employees Tesla Will Be 'Most Valuable Company On Earth, Sam Bankman-Fried Set To Enter Plea On Fraud Case, Twitter 'Should Feel Faster': Today's Top Stories ↗

December 29, 2022

Reuters

Via Benzinga

Novartis Settles Antitrust Cases Related To Generic Entry For Hypertension Drug ↗

December 29, 2022

Novartis AG (NYSE: NVS) will pay $245 million to end antitrust litigation accusing the company of trying to delay the U.S. launch of generic versions of its Exforge, which treats hypertension to lower...

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

December 23, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

3 Ridiculously Cheap Dividend Stocks That Yield More Than 3% ↗

December 22, 2022

You're getting a lot of bang for your buck with these stocks.

Via The Motley Fool

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

53 54 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novartis AG Common Stock (NY:NVS)

All News about Novartis AG Common Stock

Starting at $3.75/week.

Subscribe Today